ENYO Pharma在澳大利亚开设新的子公司作为新的临床试验管理中

StephenW

ENYO Pharma Opens a New Subsidiary in Australia as a New Managing Center for Clinical Trials
October 26, 2017 09:00 AM Eastern Daylight Time

LYON, France--(BUSINESS WIRE)--ENYO Pharma, a biopharmaceutical company developing new molecules with an innovative approach inspired by viruses, made a strategic decision and has recently decided to open its first wholly owned subsidiary in Melbourne, Australia, because of its excellent clinical trials development capabilities and attractive conditions offered by the government. The Australian Government is very supportive of biotech startups and the Victorian Government Business Office provides good business development networking. This office will be the new ENYO Pharma center to manage EYP001 (an FXR agonist) clinical trials in the Asia-Pacific region for chronic Hepatitis B. A Phase 1b study of EYP001 is currently submitted in 4 countries and two new Australian centers in Sydney and Perth have joined the study and started recruitment.

    “ENYO Pharma is currently looking forward to working in this region as the well-established clinical expertise in this part of the world adds important value to ENYO Pharma R&D efforts and specifically our expeditious development of EYP001”

ENYO Pharma bases its innovation on mimicking viral strategies to discover new cellular targets and is currently developing drug candidates in therapeutic areas such as infectious and metabolic diseases. One of the company’s leading programs is a new drug EYP001, against chronic Hepatitis B which is a major public health concern in the Asia-Pacific region. More than a half of the global population infected worldwide by Hepatitis B are located in this region, representing 129 million patients.

“ENYO Pharma is currently looking forward to working in this region as the well-established clinical expertise in this part of the world adds important value to ENYO Pharma R&D efforts and specifically our expeditious development of EYP001” commented Pietro Scalfaro, M.D., Chief Medical Officer of ENYO Pharma SA.

“Melbourne’s strong biotechnology sector is the leading research and clinical trial hub in the Asia Pacific region. ENYO Pharma is a leading biotechnology innovator in infectious diseases and the Government of Victoria is proud to welcome their new research subsidiary into Melbourne, Australia.” said the Minister for Innovation and Trade, Minister Philip Dalidakis.

ENYO Pharma's technology and pipeline - http://www.enyopharma.com/science/principle/

ENYO Pharma SA - www.enyopharma.com

StephenW

ENYO Pharma在澳大利亚开设新的子公司作为新的临床试验管理中心
2017年10月26日上午09:00东部夏令时间

法国LYON - （美国商业资讯） - ENYO Pharma是一家以病毒启发的创新方式开发新分子的生物制药公司作出了战略决策，最近决定在澳大利亚墨尔本开设第一家全资子公司，因为其优良的临床试验开发能力和政府提供的有吸引力的条件。澳大利亚政府非常支持生物技术创业公司，维多利亚州政府商业办公室提供良好的业务发展网络。该办事处将是新的ENYO Pharma中心，用于管理亚太地区慢性乙型肝炎的EYP001（一种FXR激动剂）临床试验.EYP001的1b期研究目前在四个国家和两个新的悉尼澳大利亚中心提交，珀斯加入了研究并开始招聘。

    “ENYO Pharma目前期待着在这个地区工作，因为这个世界上这一地区的成熟临床专业知识为ENYO Pharma研发工作提供了重要的价值，特别是我们快速开发EYP001”
    推荐这个

ENYO Pharma的创新基于模拟病毒策略来发现新的细胞靶标，目前正在开发治疗领域的候选药物，如感染性和代谢性疾病。该公司的主要项目之一是新药EYP001，针对慢性乙型肝炎，这是亚太地区的主要公共卫生问题。乙型肝炎感染全球的全球人口中有一半以上位于该地区，其中1.29亿患者。

“ENYO Pharma目前期待着在这个地区工作，因为在世界上这个地区已经建立起来的临床专业知识为ENYO Pharma研发工作提供了重要的价值，特别是EYP001的快速发展。”Pietro Scalfaro医学博士，首席医疗官的ENYO制药公司。

“墨尔本强大的生物科技行业是亚太地区领先的研究和临床试验中心。 ENYO Pharma是传染病领先的生物技术创新者，维多利亚州政府自豪地欢迎他们在澳大利亚墨尔本的新研究子公司。“创新与贸易部部长Philip Dalidakis部长说。

ENYO Pharma的技术和管道 - http://www.enyopharma.com/science/principle/

ENYO Pharma SA - www.enyopharma.com